Royalty Report: Drugs, Delivery, Drug Discovery – Collection: 299227


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Delivery
  • Drug Discovery
  • cardiac
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 299227

License Grant
The parties have entered into a Development, License and Supply Agreement dated January 27, 2000 for Extended Release Propranolol.

For the Development Program, Licensee engages Licensor to perform the scope of work for Development and Commercialization of AB rated Modified Release Dosage forms of Propranolol.

Licensor grants a sole and exclusive license under the Know-How with the right to sublicense within the Territory to use the Product in the manufacture of the Finished Dosage Form, and use, offer for sale, market and sell the Finished Dosage Form provided, however, that Licensee shall not grant sublicenses in the United States without the consent of Licensor, which consent shall not be unreasonably withheld.

Licensor grants a non exclusive license to use and sublicense the right to use the Trademark.

License Property
Licensor is the owner of original processes, patents, trademarks and know-how for the development and manufacture of modified release pharmaceutical products.

The Active Ingredient means Propranolol HC1.

Product means a Modified Release Composition containing the Active Ingredient and certain excipients, said compositions being bioequivalent to Inderal® LA and produced by Licensor and meeting the Specifications.

The trademark use permitted is Produced with Eurand Trademark technology.

Propranolol is a beta-blocker. Beta-blockers affect the heart and circulation (blood flow through arteries and veins). Propranolol is used to treat tremors, angina (chest pain), hypertension (high blood pressure), heart rhythm disorders, and other heart or circulatory conditions.

Propranolol HCl is a novel bedtime-dosed, extended-release formulation of this beta blocker for the treatment of hypertension.

Field of Use
The filed of use of propranolol is for the treatment of hypertension and migraines.

IPSCIO Record ID: 203528

License Grant
Licensor hereby grants to Licensee and Licensee hereby accepts, an exclusive  license, without the right to grant any sublicense, under the Patent Rights and the Know-How to use and sell Product in the Territory. No license is granted for any other product than sustained release propranolol which is bio-equivalent to to lnderal LA.
License Property
Product shall mean any and all bulk or finished pharmaceutical products in solid oral dosage form which are  developed or manufactured using the Patent Rights or Know How that contain sustained-release propranolol as the active pharmaceutical ingredient and are intended to be bioequivalent to lnderal LA.

Patent Rights means
Application Serial No. 09/554,102   Filed May 4, 2000
Application Serial No. 09/555.095   Filed May 24, 2000

Field of Use
Inderal LA (Propranolol) is a beta-blocker used to treat high blood pressure, irregular heartbeats, shaking (tremors), and other conditions. It is used after a heart attack to improve the chance of survival. It is also used to prevent migraine headaches and chest pain (angina). Inderal LA is formulated to provide a sustained release of propranolol hydrochloride

IPSCIO Record ID: 172762

License Grant
Licensor grants an exclusive license for the term of this Agreement within the territory to use the Product in the manufacture of the Finished Dosage Form, and use, offer for sale and sell the Finished Dosage Form.
License Property
The product is a spheronized, encapsulated composition containing the Active ingredient, which is the mixture of lipases, proteases and amylases,  and certain excipients.

Licensor is the owner of original processes and know-how for the development and manufacture of encapsulated pharmaceutical substances.

Field of Use
This development program is directed towards producing spheronized, encapsulated compositions containing pancreatic enzymes.

IPSCIO Record ID: 279388

License Grant
Licensor hereby grants to Licensee an exclusive royalty-bearing license within the Territory to utilize the Product to make the Finished Goods and to use, offer for sale and sell the Finished Goods.  Licensee shall own and market the Finished Goods under its own Trademark. In addition, Licensee shall refer to Licensor’s technology and trademark on the package, internal leaflet and promotional material of the Finished Goods using a trademark to be designated by Licensor. For this purpose, Licensor hereby grants Licensee a non-exclusive license to print the following wording “Produced with Licensor [Trademark to be designated]® technology”. Alternatively, Licensee shall print the trademark to be designated on the label and labeling for the Finished Goods, at a location to be designated by Licensee. Prior to printing the packaging, Licensee shall send Licensor a sample of packaging for prior approval of the above, which approval shall not be unreasonably withheld or delayed. Licensee covenants that such use of Licensor’s trademark shall be strictly in accordance with the terms of this Agreement and that all rights to and ownership of the trademark remain with Licensor. The license granted may be converted to a non-exclusive license on a country by country basis by operation relating to applicable permits.
License Property
Product means a commercially suitable capsule or tablet containing Active ingredients and certain excipients in a controlled release formulation, said composition being, or being produced using, Licensor Know-How and meeting the Specifications. Active Ingredient(s)” means cyclobenzaprine.

Licensor is the owner of original processes and know-how for the development and  manufacture of extended release pharmaceutical products.

Field of Use
Cyclobenzaprine is a medication used for muscle spasms from musculoskeletal conditions of sudden onset.

IPSCIO Record ID: 172763

License Grant
Licensor grants an exclusive license within the Territory to use, offer for sale and sell the Products. Licensee acknowledges that its license as it relates to Product A is a semi-exclusive license subject to a previous license granted to another party for the territory.
License Property
The products are gastro-protected pancreatin compositions containing the Active Ingredient, a mixture of lipases, proteases and amylases, and certain excipients, said composition being produced by Licensor and meeting the Specifications.  Those Products having USP Lipase contents of 4,500 and 10,000, all of which are included in the definition of Products.

Licensor is the owner of original processes and know-how for the manufacture of sustained release pharmaceutical substances.

Pancrelipase, a pancreatic enzyme used primarily by cystic fibrosis patents to aid in digestion, for the generic market.

Field of Use
This agreement is for the pharmaceutical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.